Correction to: Mol Cancer 17, 157 (2018)
https://doi.org/10.1186/s12943-018-0906-x
Following publication of the original article [1], a minor error was identified in the images presented in Fig. 1; specifically:
Fig. 1.
Sunitinib abrogates RCC cell invasion and metastasis via depressing miR-452-5p. a Presented are heatmap of the most differentially expressed miRNAs in peripheral blood under Sunitinib treatment (GSE32099) and between tumor tissue and pair-matched normal tissues(GSE37989). b The above analysis showed 10 miRNAs were significantly differentially expressed both in GSE32099 and GSE37989. c qRT-PCR assays for miR-452-5p expression with 0, 5 and 10 μM Sunitinib treatment in OSRC-2 and SW839 cells. d-e Representative micrographs of wound-healing assay and decrease in wound width was induced by transfection of miR-452-5p in OSRC-2 and SW839 cells versus miR-NC cells with treatment of 10 μM Sunitinib. f-g Representative images and number of invasive cells per high-power field was induced by transfection of miR-452-5p in OSRC-2 and SW839 cells versus miR-NC cells with treatment of 10 μM Sunitinib. h Orthotopic xenograft animal models were generated using miR-452-5p or miR-NC in OSRC-2 cells and mice treated with 10 μM Sunitinib. Presented are representative images (left) of abdominal metastasis viewed by IVIS system in each group 4 weeks after the orthotopic xenograft transplantation (n=8) and Quantitation of metastasis nodules shown at right. i Incidence of metastasis in orthotopic xenografts after 4 weeks. j TCGA cohort analysis of the differentially expressed levels of miR-452-5p in RCC tumor samples and pair-matched normal tissues. Each dot represents one sample. k Comparison of miR-452-5p expression in 20 paired RCC tumor tissues and adjacent normal tissues via qRT-PCR. l Relative miR-452-5p expression levels in RCC samples are presented as fold change=2(∆Ct normal-∆Ct tumor) of tumor versus matched normal tissues, 85% of which was upregulated in tumor tissues than adjacent normal tissues. m miR-452-5p expression in a series of RCC cell lines (SW839, A498, SN12-PM6 and OSRC-2) and human normal renal tubular epithelial cell line HK-2. n ROC analysis to assess the specificity and sensitivity of miR-452-5p to differentiate between RCC and normal tissues. o Kaplan–Meier analyses of the correlations between miR-452-5p expression level and overall survival of 806 patients with RCC through TCGA analysis. The median expression level was used as the cutoff. Data shown are mean±S.D. *p<0.05, **p<0.01
Fig. 1F: incorrect image used for representative image of invasive cells induced by transfection of miR-452-5p in OSRC-2 with treatment of 10 μM Sunitinib (top left image); the image has been corrected.
The corrected figure is given here. The correction does not have any effect on the results or conclusions of the paper.
Footnotes
Wei Zhai and Saiyang Li contributed equally to this work.
Contributor Information
Wei Zhai, Email: jacky_zw2002@hotmail.com.
Wei Xue, Email: xuewei@renji.com.
Yunfei Xu, Email: xuyunfeibb@sina.com.
Reference
- 1.Zhai W, Li S, Zhang J, et al. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals. Mol Cancer. 2018;17:157. doi: 10.1186/s12943-018-0906-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

